PDCD1 and Familial prostate cancer: Advanced prostate cancer is refractory to ICB, however the clinical trial (NCT02312557) evaluating dual therapy with AR inhibition and anti-PD-1 ICB achieved a response rate of 18%, underscoring the importance of AR signaling axis in mediating resistance to ICB.